About Us

The Company

Aadi Bioscience, Inc. (Aadi), is a privately held biopharmaceutical company focused on development and commercialization of nab-sirolimus (sirolimus albumin-bound nanoparticles, ABI-009), an mTOR inhibitor that leverages the albumin-based nanoparticle technology used in ABRAXANE®. Our mission is to realize the full potential of mTOR inhibition by highly efficient target suppression in mTOR driven diseases and biomarker driven patient populations.

The company has initiated submission of a rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the treatment of advanced (metastatic or locally advanced) malignant PEComa (perivascular epithelioid-cell tumor) – a rare form of sarcoma driven by mTOR activation for which there is currently no approved therapy.

Please check out Our Science and Therapeutic Programs for information about our work.